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To boost or not to boost in radiotherapy
Bogus∏aw Maciejewski1, Rafa∏ Suwiƒski1, H. Rodney Withers2,
Jack Fowler3, Jacek Fijuth4
A i m.  The aim of this paper it to analyse and discuss standard definition of the “boost” procedure in relation to clinical results
and new forms of the boost designed on physical and radiobiological bases.
M a t e r i a l  a n d  m e t h o d s.  Seventeen sets of clinical data including over 5000 cases cancer with different tumour stages
and locations and treated with various forms of “boost” method have been subtracted from literature. Effectiveness of boost
is analyzed regarding its place in combined treatment, timing and subvolume involved. Radiobiological parameter of D10 and
normalization method for biologically equivalent doses and dose intensity are used to simulated cold and not subvolumes (hils
and dales) and its influence of effectiveness on the boost delivery.
R e s u l t s.  Sequential and concomitant boost using external irradiation, although commonly used, offers LTC benefit lower
than expected. Brachytherapy, intraoperative irradiation and concurrent chemotherapy boost methods appear more effective.
Conformal radiotherapy, with or without dose-intensity modulation, allows heterogeneous increase in dose intensity within the
target volume and can be used to integrate the “boost dose” into baseline treatment (Simultaneous Integrated Boost – SIB).
Analysis of interrelationships between boost-dose; boost volume and its timing shows that a TCP benefit from boosting can
be expected when a relatively large part of the target volume is involved. Increase in boost dose above 1.2–1.3 of baseline dose
using “standard” methods does not substantially further increase the achieved TCP benefit unless hypoxic cells are a problem.
Any small uncertainties in treatment planning can ruin all potential beneficial effect of the boost. For example, a 50% dose
deficit in a very small (e.g. 1%) volume of target can decrease TCP to zero. Therefore boost benefits should be carefully weighed
against any risk of cold spots in the target volume.
C o n c l u s i o n s.  Pros and cons in discussion of the role of boost in radiotherapy lead to the important practical conclusion
that specifying “100% of prescribed dose to 95% of the target volume is not safe enough because it permits as much as 5% of
the tumour volume to be underdosed to a possibly dangerous degree. Other constraints are needed, such as minimum target
dose or requiring the tumour EUD (Equivalent Uniform Dose) to be not smaller than the prescribed tumour dose. In order to
achieve the expected effect of “burn-down” boost (optimal TCP benefit) the boost dose should be tailored to the number of
decades of surviving tumour clonogens needing to be killed by the boost.
Czy nale˝y stosowaç „boost” w radioterapii?
C e l.  Celem opracowania jest ocena i dyskusja odnoÊnie standardowej definicji „dawki uzupe∏niajàcej (boost)” z wykorzy-
staniem opublikowanych danych klinicznych oraz nowych sposobów stosowania tej metody.
M a t e r i a ∏  i m e t o d y.  Analiza dotyczy 17 badaƒ klinicznych, obejmujàcych ponad 5000 przypadków raka o ró˝nej lokali-
zacji i zaawansowaniu, w których zastosowano ró˝ne formy metody „boost”. Jej skutecznoÊç oceniano w odniesieniu do miejsca
„boostu” w sekwencji leczenia skojarzonego, czasu trwania i obj´toÊci tkanek napromienianych „dawkà uzupe∏niajàcà”.
Parametr radiobiologiczny D10 oraz metoda normalizacji dawek biologicznie równowa˝nych i intensywnoÊci dawki u˝ytej
w celu symulacji „zimnych i goràcych” ognisk w rozk∏adzie dawki promieniowania oraz ocena ich wp∏ywu na skutecznoÊç
dawki uzupe∏niajàcej.
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Introduction
To find a source of the term “boost” one should move
back to Baclesse, who introduced, in the nineteen thirties,
the shrinking field technique based on the belief that the
core of a tumour is more radioresistant than its periphery.
Demonstration in the fifties of the existence of a hypoxic
component in the tumour brought another rationale for
that technique. Three decades later, there was still
a strong belief that overall treatment time may not be
critical above 6 weeks and long treatment times could be
used for large infiltrative tumours. However, the high
doses necessary to control gross masses can not be given
to large volumes and therefore extra doses need to be
delivered with interstitial therapy or with a shrinking field
technique. These principles became central to the
planning of the majority of external irradiation treat-
ments. In 1966, in the first edition of the “Textbook of
radiotherapy” Gilbert H. Fletcher defined so-called “cone-
down boost” writing “…the dose given through small portals
over residual disease is called boost, but it is not a boost in
the biologic sense since it is given to obtain the same
probability of control as for subclinical aggregates” [1]. Since
that time the term “boost” has been unalterably used to
describe an escalation of dose which may define either
a real “biological” boost or a ”false” boost in an increasing
number of clinical situations.
Nowadays, it seems interesting to discuss whether
Fletcher’s original definition has outlived all technological
and fractionation innovations or should it be revised. The
important questions regarding boost terms include
whether they are useful and when and how they should be
given.
“Boost” variations
Since the nineteen sixties, for several decades the boost
has been simply interpreted as an additional dose
(sometimes termed dose escalation) restricted to the
reduced target volume being at the highest risk of local
failure. Therefore, the boost schedule has been intuitively
and inseparably linked to the shrinking field technique.
One of the most popular methods until the 1990s was
to deliver the boost dose to shrunken field(s) directly
after completing the baseline dose given to a large
field (Figure 1A). Increase in total dose was usually
accompanied by extension of overall treatment time.
When the kinetics and importance of accelerated
repopulation was documented and quantified such
a boost regimen has been recognized to be of lower
effectiveness although it may still be useful for slowly
proliferating tumours.
Concomitant boost therapy (CBT) was introduced in
MD Anderson Cancer Center in Houston [2] as a “boost”
dose delivered to the reduced volume during the time of
irradiation of a large field rather than afterwards. Usually
the CBT is given as a second daily fraction (with 6h
interfraction interval) in the necessary number of days
in the last 2-3 weeks of treatment. In principle it could
also be delivered in the first 2-3 weeks or during the
whole course of treatment (Figures 1, B1 and B2), but
these sequences were shown to be less effective. The use
of this concomitant form of boost has been accompanied
by the “field within the field” technique in the daily
practice in radiohterapy.
Some modifications of the CBT include the use of an
extra daily fraction on Saturday (Figure 1E) or on
Saturday and Sunday (Figure 1F) throughout the whole
course of radiation treatment, delivered to a smaller field
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W y n i k i.  Najcz´Êciej stosowana metoda wspó∏istniejàcego boostu (concomitant boost) z u˝yciem zewn´trznej wiàzki
promieniowania, przynosi zysk terapeutyczny, ale ni˝szy od oczekiwanego (13%). Inne formy „boost” z u˝yciem brachyterapii,
radioterapii Êródoperacyjnej i chemioradioterapii sà bardziej skuteczne. Terapia konformalna bez lub z u˝yciem modulacji
intensywnoÊci dawki umo˝liwia niejednorodny wzrost intensywnoÊci dawki promieniowania w obszarze tarczowym.
W konsekwencji dochodzi do integracji dawki „boost” z podstawowym napromienianiem (Równoczesny Zintegrowany
Boost – SIB). Analiza zale˝noÊci mi´dzy wartoÊcià dawki „boost”, czasem jej podania i napromieniania oraz obj´toÊcià
wykaza∏a, ˝e mo˝na oczekiwaç zysku terapeutycznego, je˝eli obszar „boost” jest wzgl´dnie du˝y. Wzrost dawki „boost”
powy˝ej 1.2-1.3 dawki podstawowej zasadniczo nie zwi´ksza uzyskanego zysku terapeutycznego. Jakakolwiek, nawet ma∏a
niedok∏adnoÊç w planowaniu leczenia, prowadzàca do obni˝enia dawki promieniowania o 50% w 1% obj´toÊci tarczowej,
niweczy ka˝dy, nawet najwy˝szy zysk terapeutyczny wynikajàcy z zastosowania „boost”, a nawet wi´cej, powoduje obni˝enie
TCP do zera. Dlatego zysk terapeutyczny, wynikajàcy z zastosowania metody „boost”, nale˝y odnosiç do ewentualnego
ryzyka „zimnych ognisk” w obj´toÊci tarczowej.
W n i o s k i.  Ocena miejsca i znaczenia „dawki uzupe∏niajàcej (boost)” w radioterapii wskazuje, ˝e specyfikacja 100%
dawki, przepisanej w 95% obj´toÊci tarczowej, nie jest dostatecznie bezpieczna, poniewa˝ pozosta∏e 5% obj´toÊci tarczowej jest
niedodawkowane, o ró˝nym stopniu niebezpieczeƒstwa. Konieczne jest przyj´cie dodatkowych kryteriów, takich jak minimalna
dopuszczalna dawka w obszarze tarczowym lub wymóg wartoÊci dawki EUD (Dawka Jednorodnie Równowa˝na), nie
ni˝szej ni˝ dawki przypisana. Ponadto, aby uzyskaç spodziewany i optymalny zysk terapeutyczny (burn-down) po zastosowaniu
metody „boost”, dawka dla tej metody powinna byç szacowana w relacji do liczby rz´dów komórek klonogennych, które nale˝y
wyja∏owiç.
Key words: radiotherapy, boost dose, dose-time-volume non-linearity
S∏owa kluczowe: radioterapia, dawka uzupe∏niajàca, nieliniowa zale˝noÊç dawki-czasu-obj´toÊci
within the large field [3, 4]. These modifications allow
completing the treatment without extending overall
treatment time (OTT) and may even shorten it by one
week or more.
Brachytherapy boost (Figure 1C) has been known
since Fletcher’s era, but it became more widely used when
the technology of High-Dose and Pulse-Dose afterloading
equipment and sonography guidance were developed.
An advantage of this form of boost is the possibility of
delivering a high dose as a single-shot or in a few fractions
to a precisely defined target and with large dose gradients
beyond the reference treatment region.
New imaging techniques, (EPID, sonography) allow
frequent control of the beam set-up and real-time
corrections. Three dimensional conformal stereotactic
radiotherapy, or single dose radiosurgery also has
a possible role for additional dose escalation as a less
invasive boost technique than conventional brachytherapy
boosts [5, 6].
As a result of the pioneering work by Abe et al [7] at
the University of Kyoto, there has been an increasing
interest in the clinical application of intraoperative
radiation therapy (IORT) as a single dose boost delivered
directly to the tumour bed (Figure 1D). A large variety of
applicators of different sizes and geometry allow tailoring
of irradiation to the individual anatomy and topography
of the tumour bed. A biological rationale for IORT is to
escalate the dose in an area of highest tumour cell
concentration. Although IORT precedes postoperative
radiotherapy by a few weeks it has been found highly
effective for rectal cancer with complete resection,
esophageal, and pancreatic cancer and as a boost during
breast conserving therapy [8, 9]. Compared to other boost
methods, the advantage of IORT is direct visualization of
the tumour bed during surgery, which enhances accurate
dose delivery.
The new technology of dose intensity modulation
(IMRT) has brought the promising opportunities to
deliver both fractions, basic and boosting, during the same
treatment session. The IMRT plan is designed to treat
simultaneously with the “sliding window” the primary
(GTV) and secondary targets at two different fraction
sizes. This method (Figure 1G) is called Simultaneous
Integrated (infield) Boost (SIB). Each of the specified
targets receives different doses per fraction and total
doses whereas number of fractions and overall treatment
time (OTT) is the same for all the targets [10, 11].
Chemotherapy has always been recognized as
a modality different from radiotherapy, although
combinations of both (neoadjuvant or adjuvant) have
been commonly used. Until recently the therapeutic gain
was found to be much lower than expected. Chemo-
therapy was considered, theoretically, as a chemoaccele-
rated boost-bolus given after completing a baseline course
of radiotherapy. From a biological point of view however,
a single dose of drug, no matter how large it could be, will
kill only a certain fraction of tumour cells surviving after
the baseline course. Therefore it is more reasonable to
administer cytostatic agent(s) in a few (fractionated)
sessions during radiotherapy. This concept led to
concurrent chemoradiation (CHTc) which can be
considered as another form of boost (Figure 1H). The
main objective in the CHTc is to explore drug–radiation
interactions to maximize tumour radioresponsiveness.
Chemo-boost administration, e.g. one a week or daily,
depends primarily on the mechanisms of radioenhan-
cement of the tumour response and toxicity to normal
tissues. Therapeutic benefit occurs only when the
enhancement of tumour response is greater than the toxic
effect. Recently, a few studies have been designed which
test a combination of two different forms of the boost
i.e. IORT+CHTc, or CBR+CHTc [9].
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Figure 1. Graphical schemes of different “boost” regimens
Evidence of boost benefits
M a t e r i a l  a n d  m e t h o d s
We took seventeen data sets including, altogether, more
than 5000 patients with different tumour types, stages
and localizations from the literature to review various
“boost’ regimens and to evaluate their efficacy. Large
clinical trials, well-known studies and some pilot and
phase I studies have been chosen to present a wide
spectrum of “boosting”. Boost-efficacy was evaluated
using local tumour control gain as an end-point, meaning,
an increase in at least 3-year local tumour control
compared with a conventional control arm or a historical
group. Acute and long-term normal tissue toxicity was
not evaluated presently.
Re s u l t s
The first evidence of a pronounced, although negative
effect of fractionated boost dose involving extension of
overall treatment time came from the RTOG 83-13 trial
(Table Ia), where the boost dose of 9.6 Gy delivered in
twice-a-day fractionation during an extra 5-6 days was
added to the baseline total dose of 72 Gy in 42 days for
head and neck cancer [12]. Almost no gain in local
tumour control (LTC) was noted compared with the basic
treatment. This result supports Fletcher’s intuition that
such a form of boost is in fact a “false” boost in the
biological sense, and this is not a way in which the boost
should be given, because the repopulation in the extra
overall time cancels out any extra cell kill from the higher
dose.
A new concept of concomitant boost (CBT) was
presented by Knee in 1986 as described by Ang et al [2]
and RTOG 9003 trial [13]. In the first study a boost of 18
Gy in 1.5 Gy fractions was delivered as a second daily
fraction for the first or the last two and half weeks of
treatment or twice-a-week during the whole course of
the basic six-week irradiation using 1.8 Gy per fraction to
the larger field. The authors observed that the CBT given
at the last part of therapy produced a 13% higher gain in
LTC than the other two forms of the CBT (Table Ib,c).
However, when this beneficial form of CBT was tested in
a four-arm trial RTOG 9003 the LTC was only 8% over
the conventional 70 Gy in 49 days.
Yan and associates [13] used a fractionated boost
dose of 20-35 Gy to residual nasopharyngeal tumours
after the basic 70 Gy in 49 days (Table Ic) and they
observed a 23% reduction in local recurrence compared
with the group in which treatment was stopped after 70
Gy. However, the price to pay was a 3-fold increase in the
incidence of radiation myelopathy (from 5.5% to 17.5%).
Yavuz et al [14] and Pos et al [15] administered two
different forms of CBT to locally advanced bladder cancer
(Table Id,e). In the former study 45 Gy in 1,8 Gy daily
fractions was delivered to the whole pelvis (PTV1) within
5 weeks (OTT). In addition, all patients received a CBT
of 22.5 Gy (15 x 1.5 Gy) to the tumour volume (PTV2)
during the third to fifth week of treatment as a second
fraction per day, to a total dose of 67.5 Gy. The authors
noted a 19% increase in the LTC compared with
a historical group and very low incidence (1%) of severe
late complications. In the second Amsterdam study the
authors went even further, by shortening the overall
treatment time to 28 days. Small pelvic fields were
irradiated to a baseline dose of 40 Gy in 2 Gy daily
fractions (PTV). A daily CBT fraction of 0.75 Gy was
delivered to the tumour area (GTV) immediately after
irradiation of the large fields, resulting in a total tumour
dose of 55 Gy in 2.75 Gy fractions. The LTC gain was
almost two times lower (10%) compared with the Yavuz
study, and severe late toxicity was surprisingly higher
(13%). Even after allowing for the difference in dose per
fraction it is difficult to explain the difference in the LTC
and late toxicity between these two studies.
One extra daily fraction per week given in
consecutive weekends with shortened OTT by one week
and using a field within the field technique can be
considered as another form of accelerated concomitant
boost (Table I m,n). The DAHANCA 7 trial used 5 boost
doses of 2 Gy on five Saturdays with OTT shortened by 1
week and achieved a 10% gain in the LTC [3]. In the
CAIR [4] trial the boost of 9 or 10 fractions of 2.0 Gy or
1.8 Gy delivered in consecutive Saturdays and Sundays
and with a shortened OTT of 40 days produced a LTC
gain of 43% (72% vs. 31%). The basic total dose
delivered to the large fields was almost the same in both
trials. However, the results of CAIR should be interpreted
carefully, since this trial included a relatively small
number of 100 cases because it was closed early for ethical
reasons (unexpectedly high gain in the LTC).
For the last 5 years Dose-Intensity Modulated
Radiotherapy (IMRT) has brought a new interesting
option for the boost. Using inverse planning and IMRT,
a treatment plan can be generated to deliver radiation
doses to two or more distinct volumes, therefore primary
and secondary targets are treated simultaneously using
different fraction sizes and different total doses, but given
with the number of fractions and OTT remaining
constant. Such a form of boost is defined as Simultaneous
Integrated (infield) Boost-SIB (Table I o,p). This form
has been found feasible [10, 11, 16] but still should be
considered experimental because follow-up is too short to
evaluate its efficacy and toxicity [17, 18]. Because of too
little data in partial normal tissue tolerances within
volumes irradiated with sharp dose gradients, biological
models such as NTCP, BED, EUD are not applicable in
the context of SIB. However, SIB has potential benefits of
increased tumour cell kill and increased probability of
local tumour control based on the small volume of the
boost. In addition SIB shortens planning time and the
overall treatment time.
Another form of IMRT-boost with dynamic MLC
has been introduced in the Sloan Kettering Cancer
Center in New York and in Chang Gung Hospital in
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Taiwan to treat nasopharyngeal cancer [17]. After
a baseline dose of 45 Gy delivered through two opposed
fields the boost of 25 Gy was given using 7-field IMRT.
The results of the 7-field IMRT were superior to the
results of the 5-field IMRT and 5-field 3D-Conformal
RT. IMRT-boost produced dose distributions that better
conform to concave targets. The pilot clinical study has
proven this method feasible and clinical trials are ongoing.
Brachytherapy (BRT) boost as either a single shot or
as a fractionated dose is one of the oldest and best
recognized methods of the boost. It is widely used in
many tumour locations. Usually it is applied immediately
after completing the basic fractionated treatment using
Low-, High- or Pulse-Dose BRT (Table I f,g,h,i). The
advantage of such a boost-form is its delivery in one or
a few days without much extension of OTT. Therefore
the overall dose intensity significantly increases. On the
other hand, an increased risk of local necrosis should be
carefully weighed, especially when the boost-dose is not
homogenously distributed and hot spots may occur. Wang
[19] published the results of intracavitary LDR-boost of 15
Gy in a single fraction after 64 Gy in 45 days given to the
nasopharynx showing consistently better local tumour
control (gain of 31%) than external beam irradiation
alone (ERT). However, some uncertainties may arise
because such excellent results have never been reported
again by any other authors. In Rotterdam, Lavendag et al
[20] treating nasopharyngeal cancer used a protocol
involving HDR-BRT boost of 4-6 fractions of 3 Gy after
60-70 Gy of ERT (Table Ig), and achieved a 20% higher
LRC than in historical controls. Severe complications
were uncommon.
In Heidelberg, Harms et al [21] have used 15-25 Gy
of Pulsed-Dose BRT boost after conserving surgery and
external radiotherapy for breast cancer patients at high
risk of local recurrence (Table Ii) and they observed a gain
in local control of 10%. Similar results were noted in
a large multicenter EORTC trial – 228831-10881
(Table Ih) with a boost fractionated dose of 16 Gy [22].
The results demonstrate the “boost benefit” as a decrease
in the recurrence risk from 7.3% to 4.3% (p<0.0001).
The largest clinical benefit was observed in patients
younger than 40 years (reduction of the local recurrence
rate from 19.5% to 10.2%) but the ratio of reductions in
recurrence rates were not different (41% and 47%
respectively). In conclusion, the trial indicates that the
boost of 16 Gy after whole breast irradiation to 50 Gy
reduces local recurrence rates by about one-half and that,
since younger women recovered more frequently, they
were the ones who achieved the greatest absolute benefit.
Intraoperative radiotherapy (IORT) used prior to
whole-breast irradiation is an interesting option for
a single shot-boost. Sedlmayer et al [8] introduced IORT-
boost as a part of conservative management of breast
cancer including conservative surgery and ERT of 51-56
Gy in 42 days. After tumorectomy the tissue surrounding
the excision cavity was treated with IORT of 9 Gy applied
to the 90% reference isodose using electrons. Whole-
breast ERT was performed after wound healing. IORT
boost of 9 Gy is biologically equivalent to about 18 Gy
given in 2Gy fractions. During the median follow-up of 26
months (14-41 months) no in-breast recurrences have
been observed. It is too early to evaluate this method,
but compared with other boost methods IORT has some
advantages, e.g. first of all – it guarantees an accurate
dose delivery, secondly – it allows complete skin sparing
and less late effects (fibrosis) may be expected than after
brachytherapy HDR-boost. Finally, IORT prolongs the
surgical procedure by only 20-30 minutes, while whole
combined treatment time can be shortened by 1-2 weeks.
IORT became an integrated modality in breast conserving
treatment in Salzburg with over 500 patients treated since
1998.
It is quite well recognized that a combination of
chemotherapy and radiation tends to maximize the anti-
tumour effect. Concurrent chemo-radiation has been
shown to improve local control and survival in several
types of tumour. Concurrent chemotherapy can be
considered as another form of boost (CHTC). The CHTC
boost combined with modest-dose radiation produces
a LTC gain higher than high-dose radiation therapy. In
the Catholic University of Rome, Valentini [9] combined
two different forms of boost in the treatment of patients
with locally advanced (T4) rectal cancer (Table Il).
Preoperative ERT of 45 Gy in 35 days was combined with
“chemo-concomitant-boost” of 5-Fluorouracil (96 h
continuous bolus of 1000 mg/m2/day in week 1 and 4)
and Mitomycin C (10 mg/m2 bolus in day 1). This
“chemo-boost” was repeated in the last week of the ERT.
After 6-8 weeks patients underwent radical surgical
resection with IORT-boost of 15 Gy to the tumour bed.
The actuarial 5-year loco-regional control rate was 33%
higher than for regular chemo-radiation combined with
surgery (91% vs. 58%). No late toxicity related to IORT
was detected in the median follow-up time of 3 years.
This combined boost seems to be most beneficial to
patients undergoing complete resection, as compared
with partial resection only. The Rome group has noted
a very high rate (85%) of sphincter preservation.
The Rome results are consistent with those from
various US centres (i.e. Massachusetts General Hospital
in Boston, MD Anderson Cancer Center in Houston).
Moreover, the Gastrointestinal Tumour Study Group
found that the combination of ERT with concurrent
chemo-boost and IORT is more effective in the treatment
of resectable pancreatic cancer than the combination of
surgery, postoperative ERT and concurrent chemo-
therapy. The incidence of local failure was 3-times lower
(17.6% vs. 51%). Perioperative morbidity and mortality
rate recorded in the Rome series was similar to that
observed in other series without IORT.
Although the results of concurrent CHTC might be
considered controversial, a few recent trials have
demonstrated an improvement in the LRC of head and
neck cancers. Apparently convincing evidence came from
the Intergroup 0099 trial [23]. In that study (Table Ir)
patients with nasopharyngeal cancer were randomly
assigned to concurrent chemotherapy with ERT of 70 Gy
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in 46 days vs. ERT alone. Cis-platin of 100 mg/m2 was
delivered on days 1,21 and 42 of ERT, followed by 3
courses of adjuvant Cis-platin and 5-Fluorouracil
(1000 mg/m2/day on days 1-5). The trial was stopped early
because of a highly significant 3-year disease-free survival
benefit of 45% (69% vs. 24%). The major criticism is
that the results in the control group were poor. However,
Cooper et al [24] reported recently a 3-year survival of
93% for patients with stage III and IV nasopharyngeal
cancer treated with a regimen similar to that used by the
Intergroup. Tumour control improvement (32%)
remained high (93% vs. 61%). In contrast, using chemo-
therapy as neoadjuvant treatment prior to radiation did
not show a pronounced gain in two different phase III
trials in MDACC and in Prince of Wales Hospital in
Hong-Kong. The authors try to explain the lack of the
LTC gain as resulting from inadequate intensity of
neoadjuvant CHT.
Therapeutic benefit for oral cavity after concomitant
boost is well documented by MD Anderson Cancer
Center studies [2]. Further increase of such benefit in
local control by 12–17% (to about 30%) was noted by
Brizel et al [25], who delivered 70 Gy in 1.25 Gy fractions
given twice-a-day in 40 days, plus a concurrent chemo-
boost of Cis-platin and 5-Fluorouracil during week 1 and
6 of irradiation. The benefit in loco-regional control
strongly correlated with improvement in disease-free and
overall survival.
A scattergram of gains in local tumour control
(LTCG) based on the present analyses of the results of
different “boost” forms does not establish a single and
simple correlation between LTC gain and the boost dose
(Figure 2). It can only be deduced that above 10 Gy and
up to the limit of 25 Gy of boost dose given in 2 Gy
fractions, 1 Gy increase in dose may, on average, produce
approximately a 1–1.5% gain in the LTC. This uncertainty
regarding the therapeutic benefit arises from a large
heterogeneity of tumor types, sizes and locations, which
are reviewed, and also from variations in boost intensity
and techniques of delivery. Clinical and biological hetero-
geneity of tumours, together with dose nonuniformity
within the target volume, suggest that great caution
should be exercised in interpreting the results. The benefit
expected from raising the dose in the boost volume is
very non-linear and may only slightly increase the Tumour
Cure Probability (TCP), whereas a small volume under-
dosed can entirely prevent a cure. The biological impact
of a boost-dose depends not only on the magnitude of
boosting, but also on its size and relative volume involved.
The present review shows that external radiotherapy,
although widely accepted, has limited “power”, and
different forms of boost may produce a higher gain in
local tumour control. On the other hand, the traditional
time for boosting immediately after completing the basic
course of irradiation and the dose fractionation pattern of
the boost are not the only solution. Single shot-boost can
be used at the beginning of treatment or even a few days
before as an intraoperative boost. Further combinations
are offered by chemo-boosts. The studies presented
suggest that chemotherapy combined as a boost with
radiation significantly enhances the tumour benefit, at
least in head and neck and rectal cancer. A recent review
from the Mayo Clinic in Rochester [26] shows, that rectal
cancer is of special interest. The rationale for using
chemo-radiation is based on the risks of relapse after
surgery alone, on evidence of radioresponsiveness to
primary or preoperative irradiation, and on the facilitation
of sphincter preservation as a result of tumour
“downstaging/downsizing”. The Gastrointestinal Tumour
Study Group trial (GTSG-7180) and North Central
Cancer Treatment Group trial (NCCTG 864751) both
show a significant improvement in local tumour control
and disease-free survival and a decreased incidence of
distant metastases, from using a concurrent, protracted
low-dose 5-Fu schedule instead of a concomitant boost of
5-Fu as a bolus.
The present review leads to the conclusion that no
single most effective boost schedule can be chosen.
Evolution of a single-boost modality into a two-or-three
component boost policy in which chemotherapy plays an
important role can be observed. The role of ongoing and
future studies is to define which boost schedule, time of
delivery, sequence and size of boost target volume can
produce optimal therapeutic benefit for specific tumour
types, sizes and locations.
When is a boost really a boost and when it might
work?
Fletcher’s original definition can be simplified to say –
a boost is an extra dose given to a target subvolume. The
answer to whether it is necessary or beneficial could be –
yes it is, but it could also be – no it is not. Such a dilemma
arises from the original definition still commonly used,
which does not specify the essence of the boost, which is
to increase local tumour control probability (TCP). This
immediately places “boosting” into the field of clinical
radiobiology. A large family of clinical dose-response
curves for tumour control probability (TCP) are generally
shallow and reflect heterogeneity in tumour and treat-
ment characteristics, such as differences in intrinsic
radioresistance, number of clonogens, rate of repopu-
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Figure 2. Scattergram of therapeutic gain in local tumour control
(≥3 yrs.) depending on boost dose. (Letter abbreviations are taken
from Table I)
lation, acute or persistent hypoxic fraction and variations
in dose fractionation patterns. In the early nineties the
problem of the TCP-dose escalation relationship has been
discussed by Thames et al [27]. The authors considered
a heterogeneous population of tumours with a repre-
sentative shallow TCP curve (Figure 3), comprised of
three equally sized subpopulations of very sensitive (A),
moderately sensitive (B) and resistant (C) tumours. An
increase in the dose that will achieve an average of 50%
control in an equal mixture of the three tumour groups
will not affect the probability of cure of sensitive (A)
tumours because they will be directly, nearly certainly,
controlled by that dose. In contrast, tumours in “C” group
are resistant and failure remains practically certain with
a modest dose escalation. Therefore, dose escalation
above the “average” dose for 50% control of a mixture of
the A B and C tumours may change the TCP of B
tumours only. Zagars et al refer to this subpopulation as
the stochastic fraction [28], where local control is
determined to some extent by chance. The outcome for
this group is not fully predictable and the probability of
control is a steep function of dose around the average
TCD50. According to Thames, the majority of clinical
trials with unselected patient populations may fail to
detect the benefit of a modest (e.g.10%) dose escalation
but it does not mean that it may not be a good strategy.
Tumour radiosensitivity is not the only item in
a consideration of “boosting”. Accelerated repopulation
with the speed increasing toward the end of week 5-7 of
conventional irradiation may, likely, neutralize the effect
of each extra dose delivered in a multifraction regimen
given after completing the baseline course of ERT
(Figure 3 – horizontal line “no”). Therefore, the physical
dose is boosted, but the biological dose is not, and such an
extra dose is completely wasted. The problem of
accelerated clonogen regrowth can be counterbalanced by
boosting the dose with minimal or no extension of overall
treatment time (Figure 3 – vertical line “yes”). This can be
achieved by single-shot BRT, concomitant boost delivered
as a second daily fraction during the main course of ERT
(e.g. in last 2 1/2 weeks), concurrent chemo-boost or by
Simultaneous Integrated Boost using IMRT (Figure 4). In
all these regimens OTT is not significantly prolonged and
can even be shortened. This is not a theoretical concept,
but evidence-based. The results of the RTOG 83-13 trial
[12], discussed earlier, convincingly show that dose
escalation with extension of overall treatment time may
gain nothing. A similar relationship was observed by
Suwiƒski et al [29] for postoperative radiotherapy
(Figure 5). The results show that the increase in dose
with extension of OTT produces no gain in the TCP, but
that a higher dose with no increase in OTT is beneficial
for TCP. On the other hand, the authors suggest that the
difference in the effect of protracted vs. shortened OTT is
an intrinsically non-linear relationship between OTT and
TCP: there is less gain in TCP by shortening OTT by
a few days than what can be lost due to protraction of
OTT over the same number of days. They also have noted
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Figure 3. Theoretical TCP curves for biologically heterogeneous
population of tumours of the same size, site and stage comprised of
subpopulations “A”, “B” and “C” of very sensitive, moderately sensitive
and resistant tumours (modified from Thames et al, 27)
Figure 4. Model cell survival curves for a tumour with 1010 cells treated
with 70 Gy in 2 Gy fraction with D10=7 Gy: (D10 is the dose decreasing
cell survival by one decade). This example shows that when
a conventional boost of even 20 Gy in 26 fractions is administrated
after completing the ERT, when repopulation is the most rapid, it can
counterbalance cell-killing and no biological gain can be expected. The
boost may become effective by delivering it as a single shot BRT, or by
a concomitant boost (CB) in the last 2 1/2 weeks of treatment or by
concurrent chemo-boost during ERT
Figure 5. Relationship between reduction in locoregional failure
probability, total dose and overall treatment time for postoperative
radiotherapy of head and neck cancer. “Horizontal” dose escalation
with OTT extension is NOT a boost because the effect of the extra
dose is neutralized by regrowth of surviving tumour clonogens.
“Vertical” increase in dose intensity – YES, is a boost 
(Suwiƒski et al, 29)
that an increase in dose intensity from 9 Gy/week to more
that 10.5 Gy/week resulted in an increase 5-year LTC by
15%. Thus, boost efficacy is not only a matter of the size
of extra dose, but also a matter of the time taken for its
delivery. This leads to two terms: dose escalation and dose
intensity, which are often misinterpreted. The first term
simply means an increase in physical dose whereas the
second one defines how many Grays are delivered per
unit of time (hour, day, week).
Consequently, dose escalation may or may not have
a biological impact whereas dose intensity does. Following
Fletcher’s intuition, dose escalation with time extension is
not a boost in the biological sense. The role of a boost is
to increase dose intensity (DI) by giving extra dose with
little or no increase in OTT. If the basic treatment is for
example 60 Gy in 42 days, and the planned boost dose is
16 Gy, then its delivery in a standard fractionated manner
needs an extra 10-11 days. For such treatment the basic
DI is 1.43 (60/42 Gy/day) and, an extra 16 Gy in 11 days
does not change the DI (76/53=1.43). Therefore, this is
not a true boost in the tumour undergoing a rapid
regrowth in its clonogen number. But if 16 Gy can be
delivered in only one extra day, then the DI will increase
to 1.77 (76/43 Gy/day) and this is a real boost for rapidly
growing tumour clonogens. Therefore, boost means an
increase in dose intensity in a biological sense, but not
necessarily dose escalation. However, this is still only
a tool of the boost, but not the essence of the matter.
When planning and delivering a boost an extra cell kill is
expected. The battle concentrates on a few tumour
clonogens, which survive a series of basic fractions with
the aim of killing them all. When an average 1 to 3 cells
survive, the TCP for the individual patient is between
37% and 5% (e–1 → e–3). An extra dose of 1 x D10 added
to the dose which reduces cell survival to an average of 1
clonogen per tumour will decrease the surviving fraction
by one decade to an average 0.1 cell/tumour which will
result an increase in the TCP from 37% to 90%. This
53% gain in local tumour control probability reflects
a “real biological boost”. The size of the extra dose and the
boost volume are only tools to achieve the goal and
a more appropriate term for an increase in “biological”
dose, as distinct from “physical boost” could be “burn
down boost”.
How large should a boost dose and boost volume be?
The biological impact of “effective” boost depends non-
linearly not only on the magnitude of the increase in dose
(size of boost) but also on its timing and boost volume [30,
31]. For tumours which accelerate the growth rate of
surviving clonogens late in the treatment an increase in
TCP can only be expected when OTT is kept as short as
possible. When subclinical tumour cell deposits are
a factor in treatment planning (elective or postoperative
boost) it should also be shortened, because rapid growth
is an inherent characteristic of small tumour deposits and
is occuring at the beginning of treatment, without the lag
period that characterizes the response of primary bulky
tumours.
When considering the size of the boost dose and
volume it is no longer mandatory to deliver a uniform
dose to whole target volume. Non-uniform dose distri-
bution is almost unavoidable in brachytherapy and
stereotactic radiotherapy and it is not a disadvantage.
Selective delivery of a higher dose to subvolumes of the
target can lead to either a small and clinically unde-
tectable increase in tumour control or a substantial
increase, depending on how large is the extra dose and is
it encompassed with the boosted subvolume. It is
commonly thought, that tumour cell density increases
towards the center of the tumour, but on the contrary
the number of clonogens is proportional to tumour
volume, and so because the volume is proportional to
the cube of tumour diameter, most clonogens are in the
outer part of a tumour cross-section. Thus, it is
unreasonable, and even risky, to assume that any part of
the edge of the CTV might have fewer cells. The PTV,
however, can be shrunk to define the size of the boost
volume. Although CT, MRI, PET and biochemical or
molecular imaging can show regions of higher cell density,
hypoxia or rapid repopulation, primary or elective boost
geometry is still subjective. Considering non-uniform dose
distributions, a single tumour or subclinical deposit can be
presented as a conglomeration of a number of
subvolumes.
Moving from theory to practice there are at least
two subvolumes, i.e. large basic PTV for the baseline
course of irradiation and a smaller one, within the large,
for a boost. Overall TCP resulting from delivery of
baseline dose to large volume and extra boost dose to
smaller subvolume will be a function of two different
TCP’s which can be calculated from the equation:
(a)
thus,
(b)
where N is initial number of tumour clonogens, VB is
relative subvolume of boost, SF2.0 is an average surviving
fraction after 2.0 Gy fraction, Di is baseline dose and DB
is boost dose. This equation is explained in detail in
Appendix 1. This could be easily rewritten using effDo or
D10 instead of SF2.0 but it will not change TCPT
quantitation.
Using equation (b) and the method proposed by
Withers (30), Tome and Fowler [31, 32], improvement in
overall TCPT was calculated depending on the baseline
TCP (standard regimen if not boosted), the size of boost
dose and boost volume relative to the primary GTV. It is
obvious that the maximum increase in TCP can be
expected when the whole PTV would be included in
homogenously escalated dose volume.
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Table II shows that a boost is not very effective when
the baseline TCP is already high, e.g. 90%, and/or it is
delivered to a small boost volume. Boost efficacy in such
a case is theoretically worthless. An exception is if hypoxic
cells are present in the boosted volume. Independently of
how large is the boost dose the results in Table II suggest
that overall TCP is essentially determined by the
percentage of tumour volume in which the dose is not
escalated. Once the boost dose is applied to a volume
larger than 50% of the GTV, gains in the TCP increase
more steeply, especially when the baseline control rates
are low. For example, if a dose producing TCP of 50%
was boosted throughout 50% of the GTV by 1 x D10 the
TCP would increase by 17% (from 50% to 67%); but if
the boost volume was enlarged from 50% to 80% of the
GTV, the TCP would increase by a further 26%, up to
93%. Increase in the boost dose itself, e.g. from 1 x D10 to
2 x D10 within the same boost volume does not produce
substantial improvement in the TCP.
Figure 6A shows that boost dose above 12–16 Gy
does not produce a significant further increase in the
TCP and respective boost curves are almost identical in
the range 18–30 Gy. Tome and Fowler [31] demonstrated
that beyond a boost dose ratio (bdr) of 1.2–1.3 the curve
for TCP reaches a plateau unless hypoxic cells are
a problem. The bdr is a ratio of dose in the boost volume
to the preboost dose received by the remainder of the
GTV.
For the present calculations “effective” D10 of 7 Gy
was taken from tumour cells assayed in vitro. However,
Withers [29] postulates that retrospective analyses of
clinical results produce a relatively shallow slope of most
TCP curves because of the heterogeneity of human
tumours in the factors determining radiocurability, and
heterogeneities of dose prescription and distribution. This
implies an effective D10 close to 20 Gy for a regimen of 2
Gy fractions. On the other hand, for single–dose
brachytherapy or radiosurgery of 18–20 Gy the D10 value
would be approximately 2.5–3.0 Gy. It may explain why
brachy-boosts have been found more effective than the
conventional ERT boost given in 2 Gy fractions (Table I).
A basic limitation for the concept of tumour boosting
is the risk of necrosis of normal tissue within the PTV,
but very high boost doses can be avoided because there is
no need to exceed “bdr” of 1.3 to obtain maximum
increase in the TCP.
455
Table II. Therapeutic gain in local tumour control (LTC) depending on the size of boost dose**
and boost volume in relation to the level of the baseline TCP
TCP increase by percentage points*
BOOST ⇒ 10% 50% 80%
VOLUME****
Boost dose in D10 1 x D10 2 x D10 1 x D10 2 x D10 1 x D10 2 x D10
Baseline TCP***
10% 3% 3% 17% 20% 42% 50%
50% 3% 3% 17% 19% 32% 36%
90% 2% 2% 4% 4% 7% 8%
* Therapeutic gain in LTC is calculated as an increase in percent points from the baseline TCP (basic treatment to whole PTV) to overall TCP
accounting the effect of boost
** D10 is the dose reducing cell survival by an average of one decade and for the present calculation D10 of 7.0 Gy was used
*** Baseline TCP is calculated for whole PTV irradiated with a homonogenous dose
**** As a percentage of tumour volume
Figure 6. Plots of the estimated increase or decrease in TCP as
a function of over- or underdosage and the size of subvolumes
involved. Subvolume coordinate is presented (A) in linear scale; (B) in
log scale. Regimen of total dose of 60 Gy homogenously delivered in
30 fraction in 42 days is assumed as a standard. Assuming initial
number of tumour clonogens N=109 and SF2=0.5 estimated TCP is
0.394. Parameters N and SF2 are held constant and changes in TCP
were calculated for changes in total dose and in the size of subvolumes
receiving the boost-dose or underdosage, using equation (6) presented
in Appendix 1 in detail
Hills and dales
Discussing advantages of boosting it has to be pointed
out that tight conformation boost field (volume) to the
margins of gross tumour mass increases the risk of
geographic underdosage. The consequences of geographic
underdose depend upon how many tumour clonogens
are relatively underdosed, and how large is the magnitude
of the underdosage. Figure 6A-(b) shows a dramatic
decline in TCP for small underdosed volumes of <20%,
but the absolute decline in TCP is influenced by the
magnitude of the underdosage. If only 20% of the tumour
were underdosed by 0.5 x D10 (3.5 Gy) TCP would
decrease by 10% but if as little as 5% of target volume
would receive a dose decreased by 12 Gy the TCP will
decrease almost to zero (Figures 6A, B).
Figure 6A shows that the TCP curve for under-
dosage of a 60 Gy minus 12 Gy is much steeper than that
for the increase by 12 Gy. This is illustrated even more
clearly in Figure 6B, where the coordinate of “boosted” or
“missed” volume is presented in a log scale. A high dose
deficit even in a small subvolume is more likely to lead to
failure of treatment than a high dose boost delivered to
a relatively larger subvolume is to lead to benefit.
Therefore small dales (Figure 7A) are more dangerous
than large beneficial hills (Figure 7B). A dose deficit
larger than 20% of the prescribed dose to 1% volume of
GTV may lead to serious loss of TCP, even if 80% of the
target receives a 10% boost. Assuming TCD40 of 60 Gy
(Figure 6) a “dale” of 12 Gy in volume of 1% ruins the
whole potential benefit of the boost, even if 80% of the
GTV receives a 20–30% boost. Practically, a dose deficit
larger than 20% in only 1% essentially reduces TCP to
zero (Figure 7A). A dose-dale becomes hazardous when
there is a 10% deficit in more than 10% of the tumour
volume. Planning to increase LTC gain by giving a boost,
one should keep in mind that any underdosage within
the target volume is a more critical and powerful
determinant of treatment outcome than optimal boost
dose delivered to the defined subvolume. Dose escalation
in small volumes of the tumour, regardless of its
magnitude, is of little value in any situation, whereas
a large dose deficit in a very small volume is a disastrous
for local tumour control.
Optimal “burn down” – boost
As discussed above, a boost dose delivered in a prolonged
overall treatment time is an escalation of dose but is not
a boost as to the biological effect in tumours such as
squamous cell carcinomas of the head and neck, in which
clonogens regenerate rapidly late in the course of
treatment. Such a “boost” may only increase the risk of
late normal tissue injury. Among ERT solutions, con-
comitant boost with no extension of OTT is commonly
used, but its efficacy is lower than expected. A single-
dose shot of BRT or IORT is likely to be more effective.
Recently, concurrent chemo-boost combined with BRT or
IORT boost has began to look promising. However,
conformal radiotherapy with heterogeneous dose
distributions, using dose intensity modulation, seems to be
an optimal resolution. Steep gradients in dose distribution
permit a higher dose per fraction within gross tumour
mass than is possible with standard therapy, and also
allow a lower dose to the peripheral volumes of PTV
(Figure 7). Therefore, within each daily fraction exposure
the dose intensity to the tumour can be selectively
increased. This form of Simultaneous Integrated Boost
(SIB) can be used for the whole course of treatment or as
a technical boost during the second half or one third the
course of irradiation: the treatment may begin as standard
dose distribution and then the dose intensity to the
tumour can be selectively increased.
Such complex beam arrangements produce steep
dose gradients. For example, if the whole tumour is
encompassed at the 80% isodose, and 70 Gy in 7 weeks is
prescribed to the PTV, the dose per fraction within the
tumour will increase by a factor ranging up to 1.25
(100/80) and the total dose would range between 70 Gy
and 87.5 Gy resulting in acceleration of dose intensity up
to 25% (Figure 7B). Obviously, dose intensity could be
further increased by prescribing the dose to a lower
percent rate isodose. Furthermore, the higher dose per
fraction yields an increase in the biological dose
456
Figure 7. Dose volume histograms for conformal radiotherapy with
“cold dale” (A) and “hot hill” (B)
(A) DVH follows the specification “full prescribed dose to 95% of the
tumour volume”, but the long tail-back shoulder (cold dale) illustrates
50% dose-deficit in 1% volumes and 30% deficit in 2% volume. Such
“cold dale” completely ruin not only the potential benefit of a boost,
but in the example shown, they eliminate any chance of tumour control
(B) SIB planning with 80% isodose encompassing PTV provides at
least 25% increase in physical dose within GTV (boost hot-hill)
illustrated in the DVH by the vertical tail. The size of the “hot-hill tail”
corresponds with the size of boost and subvolume involved
depending on the α/β value. Many tumours currently
treated with conformal therapy have a relatively slow
proliferation profile (e.g. prostate, meningiomas,
chordomas). If such tumours are characterized by a low
α/β value of 2.0 Gy and if the fraction dose is 2.5 Gy,
compared with 2.0 Gy in the remaining part of PTV, then
the 25% increase in physical dose would be amplified by
a further 12.5% and the biological dose within the GTV
would be 37.5% higher than the dose in the remaining
PTV. However, it has to be remembered that any increase
in dose intensity in only a small volume of the tumour
will not improve therapeutic gain, independent on the
type or magnitude of the boost used. The old rule of
thumb is that not more than 10% less dose in not more
than 10% of the target volume is not bad, but according
to Tome and Fowler [32], it conceals the highly
asymmetrical nature of such a guideline. The DVH can
correctly demonstrate the full prescribed dose to 95% of
the tumour volume, but the long tail-back (Figure 7A),
not always readily visible in the DVH but representing
a 50% dose deficit in 1% volume, will reduce TCP to
zero. Thus, prescription of a 100% dose to 95% of the
target volume is not safe enough, because it permits as
much as 5% of the tumour volume to be underdosed to
a possibly dangerous degree. To avoid such a risk of small
cold dales and to achieve the expected benefit of boost
dose, planning should be performed carefully and
precisely. It also indicated that other constraints are
needed, such as a minimum target dose or requiring that
the tumour EUD (Equivalent Uniform Dose, i.e. equal
total cell kill) should not be smaller than the prescribed
tumour dose. Finally, in order to achieve the effect of
burn-down boost (optimal TCP benefit), the size of the
boost dose should be tailored to the number of decades of
the surviving tumour clonogens expected to be killed by
the boost.
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Appendix 1
Tumour cure probability (TCP) is exponential function of
an average number of the survived tumour clonogens (x):
(1)
where x=N*SF, and an N is initial number of tumour
clonogens. SF is surviving fraction and for fractionated
regimen “i” SFi can be calculated from:
(2)
where SF2.0 is an average surviving fraction after 2.0 Gy
and Di is a total dose for regimen “i”.
Using equation (1) and (2), TCP equals:
(3)
If boost dose Db is delivered to subvolume VB which is
a part of target volume, i.e. PTVi(Vi) then VB receives
total dose DB which is a sum of the baseline dose and an
extra boost dose:
DB = Di + Db and it is delivered
to
relative boost subvolume VB =
Vb/Vi which reflects respective
proportion of initial number of
tumour clonogens. Consequently
the remaining subvolume of PTV
receiving only baseline dose is
Vi = 1 – VB
Because both subvolumes contain different initial number
of clonogens irradiated with different total doses Di and
DB, the TCP for these subvolumes will also be different
and overall TCPtotal equals:
(4)
Using equation (3) and (4) overall TCP equals:
(5)
and finally
(6)
Example: After baseline dose (Di) of 60 Gy given to
whole PTV containing 109 cells it was decided to delivered
a boost dose of 9 Gy to 90% of the PTV volume. If
surviving fraction after 2 Gy is SF2.0 = 0.5 what would
be overall therapeutic benefit in the TCP?
Solution: For 60 Gy in 30 fraction (Di) without boost the
TCP calculated using equation (3) is
(7)
After boost schedule parameters are as follows:
N = 109 DB = 69 Gy
Di = 60 Gy VB = 0.9
Vi = (1-0.9)=0.1 SF2.0 = 0.5
Using equation (6) TCPtotal would be:
(8)
(9)
Answer: By giving 9 Gy boost to 90% of the PTV overall
TCP increases from 39% to 87.8%, then therapeutic gain
is 48.8%
.TCP 0 878total=
.0 1301=-
[ . ]10 0 1301 109 9) )=- =-
[ ( . . )]10 0 9313 10 0 3704 109 10 10) ) )=- +- -
[ ( . . . . )]L TCP 10 0 1 0 5 0 9 0 5 10/ /n total
9 60 2 69 2) ) ) #=- +
%39,
e .0 931= -
TCP e ( . )tans dard
10 0 5 /9 60 2= )-
TCP e [ {( ) }]total
V SF V SFN 1 .
/ .
.
/ .
B
Di
B
DB
2 0
2 0
2 0
2 0
= ) : :- - +
TCP e e[ ( ) ] [ ]total
V SF N V SFN 1 .
/ .
.
/ .
B
Di
B
DB
2 0
2 0
2 0
2 0
)= ) : ) :- - -
TCP TCP TCPtotal B1)=
TCP e [ ]i
N SF .
( / . )Di
2 0
2 0
= $-
SFSF .
( )D
i 2 0
/ .i 2 0=
TCP e x= -
458
TCPi
Vi = 1 – VB, Di
TCPB
VB,DB
